BPC-157 vs KPV
How they differ
- FDA status, the same for both (Not FDA-approved). BPC-157: Not an FDA-approved drug.1 KPV: Not an FDA-approved drug.2
- Kinds of studies cited. BPC-157: limited human data. KPV: animal and lab studies only. How these labels are assigned
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | BPC-157 | KPV |
|---|---|---|
| What it is | A 15-amino-acid peptide. FDA describes it as a fragment of a protein originally isolated from human gastric juice.1 | A peptide of three amino acids: lysine, proline and valine. Research FDA reviewed describes it as the end segment of alpha-melanocyte-stimulating hormone.2 |
| FDA status | Not FDA-approved Not an FDA-approved drug1 Not FDA-approved. FDA staff recommended in May 2026 against adding it to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, BPC-157 is one of six listed peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement action.1,3,4 | Not FDA-approved Not an FDA-approved drug2 Not FDA-approved. FDA staff recommended in May 2026 against adding KPV to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, KPV acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.2,3,4 |
| HHS compounding policy, October 30, 2026 | In the policy: one of the six peptides it lists.4 | In the policy: one of the six peptides it lists.4 |
| FDA compounding safety-risk page | Listed. FDA’s compounding safety-risk page, last updated April 22, 2026, lists BPC-157 among substances whose nominations were withdrawn and says FDA lacks enough information to know whether it would cause harm in people.5 | Listed. FDA’s compounding safety-risk page, last updated April 22, 2026, lists KPV among substances whose nominations were withdrawn and says FDA has not identified any human exposure data for it.5 |
| Kinds of studies cited |
|
|
| Records collected | 0 ClinicalTrials.gov records and 11 PubMed records collected | |
| Area of study | ||
| Latest dated events |
|
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1FDA briefing document for BPC-157-related bulk drug substances ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 2FDA briefing document for KPV ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 3Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 4HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 5Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 6BPC 157 for Acute Hamstring Muscle Strain Repair · record history version 1 · last update posted 2026-02-27 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 7ClinicalTrials.gov record NCT07803250 · retained source version 2026-09-03:67a2d48128fcdff7f261f5c04e4a69cfe170396b0726d611a8db06ad7256abc0 ↗
ClinicalTrials.gov · Official source · Source checked September 9, 2026
- 8July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026